Desensitizing mast cells by co-presentation of antigens with high affinity mast cell siglec ligands
US10994006B2 · kind B2 · utility
0Cited by
0References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 7, 2017 |
| Grant date | May 4, 2021 |
| Priority date | — |
| Expiry date | Jul 7, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55555
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods are described herein that are useful for treating and inhibiting allergic conditions, including reducing the incidence of mast cell mediated anaphylaxis in subjects. The compositions include a carrier that displays an antigen and a Siglec ligand that binds to a Siglec on a mast cell.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.